NASDAQ:ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.'s revenue grew 65.2% in fiscal 2025 to $3.7B while operating margin rose to 13.5%, its highest in 10 years. Free cash flow was $465.4M, 12.5% of revenue, and the diluted share count rose 5.5%.Summary generated from Alnylam Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.7B
Revenue growth+65.2%
Revenue, 5-yr CAGR+49.8%
Gross margin81.8%
Operating margin13.5%
Net margin8.4%
ROICn/a
Return on equity73.3%
Debt / equityn/a
Free cash flow$465.4M
FCF margin12.5%
Share count change+5.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 844 | 1,037 | 1,828 | 2,248 | 3,714 |
| Operating income | −709 | −785 | −282 | −177 | 502 |
| Net income | −853 | −1,131 | −440 | −278 | 314 |
| Free cash flow | −718 | −613 | 42 | −43 | 465 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 4Insider transaction report
Sep 22, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KDirector or officer change
May 27, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026 - 8-KResults of operations and financial condition
Apr 30, 2026 - DEF 14AProxy statement
Apr 6, 2026